Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial

RCT (n=265) reports no overall survival benefit after adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery (median 41.7 vs. 41.2 months) and more frequent postoperative late complications with this combination.

Source:

The Lancet Oncology